Paul Hastings Advised Leerink Partners on PepGen's $80.1M Underwritten Offering
February 08, 2024
February 08, 2024
LOS ANGELES, California, Feb. 8 -- Paul Hastings, a law firm, issued the following news:
Paul Hastings LLP advised Leerink Partners as sole book running manager in connection with PepGen, Inc.,'s underwritten offering of 7,530,000 shares of common stock at $10.635 per share.
The gross proceeds are expected to be approximately $80.1 million. PepGen, Inc., (Nasdaq: PEPG) is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therap . . .
Paul Hastings LLP advised Leerink Partners as sole book running manager in connection with PepGen, Inc.,'s underwritten offering of 7,530,000 shares of common stock at $10.635 per share.
The gross proceeds are expected to be approximately $80.1 million. PepGen, Inc., (Nasdaq: PEPG) is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therap . . .